These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 19010918)

  • 21. Dendritic cells from spondylarthritis-prone HLA-B27-transgenic rats display altered cytoskeletal dynamics, class II major histocompatibility complex expression, and viability.
    Dhaenens M; Fert I; Glatigny S; Haerinck S; Poulain C; Donnadieu E; Hacquard-Bouder C; André C; Elewaut D; Deforce D; Breban M
    Arthritis Rheum; 2009 Sep; 60(9):2622-32. PubMed ID: 19714626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DC therapy induces long-term NK reactivity to tumors via host DC.
    Shimizu K; Fujii S
    Eur J Immunol; 2009 Feb; 39(2):457-68. PubMed ID: 19180466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor responses.
    Lee CH; Chiang YH; Chang SE; Chong CL; Cheng BM; Roffler SR
    Clin Cancer Res; 2009 Apr; 15(8):2756-66. PubMed ID: 19318495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dendritic cells use endocytic pathway for cross-priming class Ib MHC-restricted CD8alphaalpha+TCRalphabeta+ T cells with regulatory properties.
    Smith TR; Tang X; Maricic I; Garcia Z; Fanchiang S; Kumar V
    J Immunol; 2009 Jun; 182(11):6959-68. PubMed ID: 19454693
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor-educated CD11bhighIalow regulatory dendritic cells suppress T cell response through arginase I.
    Liu Q; Zhang C; Sun A; Zheng Y; Wang L; Cao X
    J Immunol; 2009 May; 182(10):6207-16. PubMed ID: 19414774
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post-apoptotic tumors are more palatable to dendritic cells and enhance their antigen cross-presentation activity.
    Brusa D; Garetto S; Chiorino G; Scatolini M; Migliore E; Camussi G; Matera L
    Vaccine; 2008 Nov; 26(50):6422-32. PubMed ID: 18848858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploiting dendritic cells and natural killer T cells in immunotherapy against malignancies.
    Fujii S
    Trends Immunol; 2008 May; 29(5):242-9. PubMed ID: 18372215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased vaccination efficiency with apoptotic cells by silica-induced, dendritic-like cells.
    Massé D; Voisine C; Henry F; Cordel S; Barbieux I; Josien R; Meflah K; Grégoire M; Lieubeau B
    Cancer Res; 2002 Feb; 62(4):1050-6. PubMed ID: 11861381
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
    Jasani B; Navabi H; Adams M
    Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S; Lee JB; Lee GK; Chang J
    Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dendritic cells from bench to bedside and back.
    Adema GJ
    Immunol Lett; 2009 Feb; 122(2):128-30. PubMed ID: 19121337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells.
    Fujisawa Y; Nabekura T; Nakao T; Nakamura Y; Takahashi T; Kawachi Y; Otsuka F; Onodera M
    Exp Dermatol; 2009 Apr; 18(4):396-403. PubMed ID: 19054057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spleen but not tumor infiltration by dendritic and T cells is increased by intravenous adenovirus-Flt3 ligand injection.
    Solheim JC; Reber AJ; Ashour AE; Robinson S; Futakuchi M; Kurz SG; Hood K; Fields RR; Shafer LR; Cornell D; Sutjipto S; Zurawski S; LaFace DM; Singh RK; Talmadge JE
    Cancer Gene Ther; 2007 Apr; 14(4):364-71. PubMed ID: 17235356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monocyte and dendritic cell recruitment and activation during oral Salmonella infection.
    Wick MJ
    Immunol Lett; 2007 Oct; 112(2):68-74. PubMed ID: 17720254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autologous dendritic cells loaded with apoptotic tumor cells induce T cell-mediated immune responses against breast cancer in vitro.
    Delirezh N; Moazzeni SM; Shokri F; Shokrgozar MA; Atri M; Kokhaei P
    Cell Immunol; 2009; 257(1-2):23-31. PubMed ID: 19306994
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effective osteosarcoma cytolysis using cytokine-induced killer cells pre-inoculated with tumor RNA-pulsed dendritic cells.
    Wongkajornsilp A; Sangsuriyong S; Hongeng S; Waikakul S; Asavamongkolkul A; Huabprasert S
    J Orthop Res; 2005 Nov; 23(6):1460-6. PubMed ID: 15908161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dendritic cell-based cancer immunotherapies.
    Fujii S; Takayama T; Asakura M; Aki K; Fujimoto K; Shimizu K
    Arch Immunol Ther Exp (Warsz); 2009; 57(3):189-98. PubMed ID: 19479202
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Specific antitumor effects of tumor vaccine produced by autologous dendritic cells transfected with allogeneic osteosarcoma total RNA through electroporation in rats.
    Yu Z; Sun H; Zhang T; Yang T; Long H; Ma B
    Cancer Biol Ther; 2009 May; 8(10):973-80. PubMed ID: 19287216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Major role for CD8 T cells in the protection against Toxoplasma gondii following dendritic cell vaccination.
    Guiton R; Zagani R; Dimier-Poisson I
    Parasite Immunol; 2009 Oct; 31(10):631-40. PubMed ID: 19751475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.